The "Halftime Report" traders give their top picks to watch for the second half.
WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 202

10 Stocks For 2023

04:56pm, Friday, 23'rd Dec 2022
The outlook for stocks in 2023 is very uncertain, with the risk of a recession. The Federal Reserve is very likely to increase interest rates throughout 2023.

Grade My Trade: SMH & DHR

01:32pm, Monday, 19'th Dec 2022
The ‘Halftime Report' investment committee, Shannon Saccocia, Sarat Sethi, Joe Terranova and Jim Lebenthal, weigh in on the Danaher and semis trade.
Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.
Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.
The article discusses Danaher's business strategy, profitability, past and expected future growth, balance sheet quality, risks and dividend safety. Danaher is a great company that qualifies as a Pete
Danaher Corporation (NYSE:DHR ) Evercore ISI HealthCONx Conference November 30, 2022 10:30 AM ET Company Participants Rainer Blair – Chief Executive Officer Conference Call Participants Vijay Kumar
WASHINGTON , Nov. 22, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf

The 7 Most Undervalued Value Stocks to Buy Now

10:50pm, Saturday, 12'th Nov 2022
Value stocks have seen a resurgence in demand during 2022. Rising interest rates increase borrowing costs, making speculative behavior less appealing.
Calvert Equity Fund is an ESG-focused portfolio that's built to make it through tough times. The best mutual fund's steely defense, though, is also a weapon.

Stock Market Sell-Off: Is Danaher Stock a Buy?

04:45pm, Friday, 28'th Oct 2022
The life sciences and diagnostics company's guidance is getting complicated.
Cramer explained why investors shouldn't have sold off shares of Danaher after the company reported earnings this week.
The life sciences and medical technology company beat earnings estimates in the third quarter but narrowed its 2022 bioprocessing revenue growth forecast.
Danaher's (DHR) Q3 results benefit from higher revenues across all segments. Organic sales rise 10%, while acquisition//divestitures boost sales by 1.5%.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE